Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate

Alejandro S. Godoy,1,3,4* Ivy Chung,6,7* Viviana P. Montecinos,2,3 Ralph Buttyan,8 Candace S. Johnson,5 and Gary J. Smith4

1Department of Physiology, 2Department of Hematology Oncology, and 3Center for Translational Research in Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile; 4Department of Urology and 5Department of Pharmacology, Roswell Park Cancer Institute, Buffalo, New York; 6Department of Pharmacology, Faculty of Medicine, and 7University of Malaya Cancer Research Institute, University of Malaya, Kuala Lumpur, Malaysia; and 8Vancouver Prostate Centre, Vancouver, British Columbia, Canada

Submitted 29 November 2012; accepted in final form 1 April 2013

Godoy AS, Chung I, Montecinos VP, Buttyan R, Johnson CS, Smith GJ. Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate. Am J Physiol Endocrinol Metab 304: E1131–E1139, 2013. First published April 2, 2013; doi:10.1152/ajpendo.00602.2012.—Forty years ago, Judah Folkman (Folkman. N Engl J Med 285: 1182–1186, 1971) proposed that tumor growth might be controlled by limiting formation of new blood vessels (angiogenesis) needed to supply a growing tumor with oxygen and nutrients. To this end, numerous “antiangiogenic” agents have been developed and tested for therapeutic efficacy in cancer patients, including prostate cancer (CaP) patients, with limited success. Despite the lack of clinical efficacy of lead antiangiogenic therapeutics in CaP patients, recent published evidence continues to support the idea that prostate tumor vasculature provides a reasonable target for development of new therapeutics. Particularly relevant to antiangiogenic therapies targeted to the prostate is the observation that specific hormones can affect the survival and vascular function of prostate endothelial cells within normal and malignant prostate tissues. Here, we review the evidence demonstrating that both androgen(s) and vitamin D significantly impact the growth and survival of endothelial cells residing within prostate cancer and that systemic changes in circulating androgen or vitamin D drastically affect blood flow and vascularity of prostate tissue. Furthermore, recent evidence will be discussed about the expression of the receptors for both androgen and vitamin D in prostate endothelial cells that argues for direct effects of these hormone-activated receptors on the biology of endothelial cells. Based on this literature, we propose that prostate tumor vasculature represents an unexplored target for modulation of tumor growth. A better understanding of androgen and vitamin D effects on prostate endothelial cells will support development of more effective angiogenesis-targeting therapeutics for CaP patients.

androgens; androgen receptor; vitamin D; endothelium; prostate cancer

Lack of Success in Targeting Angiogenesis in Prostate Cancer

PROSTATE CANCER IS A COMMON MALIGNANCY in humans, representing the second leading cause of cancer-related deaths in men (87). The pervasiveness of prostate cancer in the male population has stimulated extensive efforts to develop better therapeutics to treat this disease, especially when the disease has progressed to an advanced stage and can no longer be controlled by surgery or radiation. Increasing evidence has demonstrated recently that the tumor microenvironment has a role equally important to cancer cells in the progression of the tumor (35, 49). One of the key components in the tumor microenvironment thought to have a critical role in tumor progression is the vasculature. In 1971, Judah Folkman proposed a new approach for elimination of tumors by targeting the blood vessels that supply oxygen and nutrients to the tumor (24). He hypothesized that tumor growth is facilitated by constant expansion of the vascular network (a process referred to as angiogenesis) to support the expanding tumor mass and that “antiangiogenic” therapeutics might be used singularly, or in conjunction with other therapeutics, to control tumor growth. Antiangiogenic therapies promised a rational approach, and multiple druggable targets were identified in experimental model systems. Based upon preclinical studies in vivo, pharmaceutical companies developed several novel antiangiogenic agents that extended the survival of patients, but only marginally. For example, bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was approved by the FDA as a first-line therapy for colorectal cancer, non-small...
cell lung cancer, and metastatic renal cell carcinoma and as a second-line therapy for colorectal cancer and glioblastoma multiforme (19, 41). Moreover, small-molecule tyrosine kinase inhibitors such as sunitinib, sorafenib, and pazopanib, which target VEGF receptor, platelet-derived growth factor (PDGF) receptor, and other kinases (KIT, Ret, BRAF, and Flt-3), were approved as monotherapies for the treatment of metastatic renal cell carcinoma (19). However, despite some clinical successes, antiangiogenic agents do not appear to be the “magic bullet” for treatment of solid tumors that was anticipated. In a phase III trial, treatment with bevacizumab in combination with either docetaxel plus prednisone or prednisone alone in patients with advanced prostate cancer did not improve the overall survival significantly (19). Despite such disappointing results, research continues to indicate that prostate vasculature has an important role in regulating the size and function of prostate malignancies (3, 11, 36, 37, 45, 89, 94). This review investigates the potential biological role of two hormone receptors (androgen and vitamin D receptors) in modulating angiogenesis in prostate cancer. A better understanding of the direct role of these receptors in human prostate endothelial cells may further justify their potential as new targets for antiangiogenic therapies.

Androgens are a class of steroid hormones that primarily determine prostate development and prostate tumor growth. Therapies designed to lower circulating and tissue levels of androgen in prostate cancer patients remain the most effective therapy for advanced disease (65). Cellular responses to androgens are mediated mainly by the androgen receptor (AR) protein, which is expressed highly in both normal prostate luminal epithelial cells and in prostate cancer cells. In fact, expression of endogenous AR is important in regulation of the proliferative and differentiation state in prostate cancer cells (38, 76). Even in the absence of circulating testicular androgens, the maintenance of AR expression/function is critical for proliferation of castration-resistant prostate cancer cells (104). In addition, AR activity is involved directly in regulation of the propensity of prostate cancer cells to undergo apoptosis in vitro in response to noxious stimuli; growth of prostate cancer cells in androgen-free medium renders the cells more sensitive to apoptotic death in response to radiation or chemotherapy (60). Consequently, the prostate cancer research community has focused on developing therapeutic modalities to control aberrant AR activity in prostate cancer cells, particularly castration-recurrent prostate cancer cells, to both reduce proliferation and block the inhibition of apoptosis in response to therapeutic modalities. However, the epithelial cell-specific focus neglects compelling evidence that endothelial cells within the prostate tumor microenvironment also express AR (30). AR expression in prostate endothelial cells may directly regulate their differentiation state and viability and, therefore, indirectly regulate the viability and differentiation of the epithelial compartment of benign and malignant prostate tissue. Indeed, Cunha et al. (16) showed many years ago that AR expression in the mesenchymal compartment, not the epithelial compartment, during prostate organogenesis was indispensable for the development and growth of normal prostate epithelium.

Likewise, vitamin D receptor (VDR) is expressed in both prostate epithelial and prostate cancer cells, and there is extensive evidence that vitamin D-induced signaling mediated through binding to VDR can significantly slow the growth of prostate cancer cells in vitro and in vivo (in animal models) (21, 91, 105). Not surprisingly, VDR is also expressed in nonepithelial cells of prostate cancers as well as in the benign stroma around prostate tumors (53). However, the relevance of VDR within the nonepithelial cells of prostate cancer or benign stromal cells to tumor cell growth or differentiation, respectively, is not clear.

Androgen Action on Endothelium of the Prostate and Prostate Tumor

More than 10 years ago, Ralph Buttyan and Anders Bergh independently demonstrated that the first physiological effect of androgen deprivation in the rat prostate gland was a drastic reduction in blood flow (55, 82, 83). Perturbation of the prosthetic blood flow was evident as early as 18 h after castration and coincided with the appearance of apoptotic endothelial cells in the rat prostate (83, 85). The reduction of blood flow was associated with the induction of an hypoxic environment in the prostate, with a 20-fold increase in hypoxia-inducible factor-1α (HIF-1α) protein observed at 48 h postcastration (84). Also, the reduction in blood flow was associated with major reductions in epithelial “weight,” stromal weight, blood vessel luminal weight, and number of endothelial cells 1 wk after castration (26). Both groups hypothesized that a large proportion of prostate epithelial cell loss was in fact an indirect effect caused by hypoxic/ischemic conditions that resulted from castration-induced endothelial cell death. Rat prostate endothelial cells were reported to lack expression of AR (77); therefore, both groups concluded that an androgen-regulated intermediary paracrine molecule synthesized by AR-expressing prostate epithelial or stromal cells regulated endothelial cell survival (23).

In humans, AR expression in endothelial cells has been observed in several benign tissues, including skin (8, 57), salivary gland (54), bone (1), bone marrow (61), corpora cavernosa (81), and skeletal muscle (90). Our group and others (20, 30) reported expression of functional AR in endothelial cells from benign prostate and prostate cancer (CaP), suggesting a potential role for AR in regulation of human prostate vascular endothelial cell homeostasis. Supporting this hypothesis, withdrawal of androgenic signaling by AR antagonists (e.g., flutamide and bicalutamide) and inhibitors of steroid metabolism (e.g., finasteride and dutasteride) reduced hematuria during prostate surgery and in patients with benign prostatic hyperplasia (BPH) (18, 31, 59, 73, 74, 95). More recently, two clinical studies (4, 52) showed that combination therapy with bicalutamide-goserelin (a gonadotropin-releasing hormone agonist) and dutasteride (inhibitor of 5α-reductase isoenzymes types 1 and 2) induced profound vascular collapse in human CaP patients and reduced prostatic tissue vascularity. Our group demonstrated that acute prostate vascular involution was induced by androgen withdrawal in primary xenografts of benign or malignant human prostate tissue transplanted into severe combined immunodeficiency mice in which the vasculature was of human origin (29). In this preclinical model, vascular involution was correlated temporally with the induction of apoptosis in prostate endothelial cells, indicating that testicular androgen signaling (testosterone → dihydrotestosterone → AR activation) had an important role in the maintenance of prostate endothelial cell homeostasis in intact men. This observation also suggested that androgen ablation can negatively affect endothelial cell viability in human prostate tissue independent of epithelial cell death (29).
Our studies strongly suggested that direct regulation of endothelial cell survival and proliferation may be a new biological role of AR in humans (30). Although possibly not a phenomenon general in all human organs, this concept has been validated in other human endothelial cell models (92, 93). A recent study in primary cultures of human aortic endothelial cells showed that AR activation led to moderate (a less than 2-fold increase) upregulation of VEGF-A, cyclin A, and cyclin D1 mRNA expression measured by real-time PCR; the latter two factors are involved in cell cycle progression (9). Nevertheless, the molecular targets of AR signaling in human endothelial cells are largely unknown (Fig. 2), and further elucidation of the mechanism of androgen action in human prostate endothelial cells will provide a better understanding of the effects of androgen ablation therapy on the tumor microenvironment.

Potential Role of Adrenal Androgens in Modulation of Prostate Endothelial Cell Homeostasis

Circulating androgens are formed primarily in the testis (testosterone) and in the adrenal gland [dehydroepiandrosterone (DHEA) and androstenedione] (44) (Fig. 1). The biological role of adrenal androgens (DHEA and DHEA derivatives) has not been studied in prostate endothelial cells. However, an increasing body of evidence in other endothelial cell models suggests that DHEA (and metabolites) may directly activate intracellular signaling pathways to mediate biological actions in human endothelial cells. (25, 58, 88). Binding of DHEA to cell surface receptors stimulated phosphorylation of Akt and sustained activity of endothelial nitric oxide synthase, which resulted in increased production of the vasodilator nitric oxide (25). Akt is known to phosphorylate the forkhead transcription factor FoxO1, leading to its nuclear exclusion (51, 99). Phosphorylated FoxO1 regulates cellular proliferation, differentiation, apoptosis, and glucose homeostasis (2, 32, 70) and has an important role in modulation of vascular tone and proliferation (10). Moreover, mice that lack FoxO1 expression die in utero due to improper vascular development (27).

Whereas DHEA has profound direct effects on endothelial cell function mediated through direct binding to membrane receptors, as well as indirect effects mediated through conversion to more active androgenic or estrogenic metabolites, DHEA metabolites that are not on the pathway to active androgens also have significant effects on endothelial cells (Fig. 1). For example, 3β-androstenediol can inhibit inflammatory responses induced by tumor necrosis factor-α and lipopolysaccharide in human endothelial cells (71). Androsterone was reported to be a ligand for farnesoid X receptor, a nuclear receptor that modulates lung endothelial cell homeostasis (7, 40, 100). Notably, oxidized metabolites of DHEA activated ERβ to almost the same extent as 17β-estradiol (101). Unpublished data from our laboratory demonstrated that human endothelial cells freshly isolated from benign and malignant human prostate tissue expressed all of the enzymes necessary to produce the complete diversity of DHEA metabolites. This suggests that the adrenal androgen DHEA and its metabolites can directly modulate through autocrine mechanisms and prostate endothelial cell homeostasis (Godoy AS and Smith GJ, unpublished observations).

Although serum levels of testosterone fall to undetectable during androgen deprivation therapy (ADT), there is a continuous presence of circulating DHEA, suggesting that DHEA remains a key source of androgen precursors within the prostate tissue microenvironment (80). Since endothelial cells within the prostate are sensitive to the effects of both testicular and adrenal androgens, these cells represent a high-value, but unexplored, therapeutic cellular target for therapies targeted at the androgen axis. Hence, further understanding of AR signaling in these cells may improve the outcome of ADT.

Expression and Activity of VDR in Tumor Endothelium

Calcitriol (1,25-D3), the active metabolite of vitamin D, is a central factor in regulation of bone and mineral metabolism (6, 79). Studies have shown that calcitriol affects the endothelium of various tissues by regulation of endothelial cell proliferation and differentiation (14, 43, 72). Most of the biological actions of calcitriol are believed to be mediated by a high-affinity nuclear receptor, the VDR (39). VDR expression in endothelial cells was first demonstrated in capillary and venule endothelial cells of normal human skin and endothelial cells isolated from human umbilical vein and bovine aorta (62, 63). More recently, VDR expression was observed in tumor endothelium (5, 14) as well as in circulating endothelial progenitor cells (15).

Despite substantial interest in targeting the VDR signaling axis in the treatment of prostate cancer (97), very little is known about the effects of calcitriol on the vasculature within prostate tumors. There is no direct evidence that endothelial cells in human prostate cancer express VDR and respond to calcitriol’s antiproliferative effects. However, CYP24, a well-known target of activated VDR, was expressed in the endothelium of human prostate cancers. This suggests that the VDR pathway may be activated and have a role in governing the biology of prostate endothelium (17).

Studies from others demonstrated that treatment of calcitriol can decrease vessel density VEGF expression in retinoblas-
calcium-regulated cell growth. The results of this study suggest that VDR expression and promoter activity differ between different endothelial cell populations, and that these differences may be due to variations in the microenvironment.

Effects of VDR Signaling Activation in Tumor Endothelium in Vitro and in Vivo

Calcitriol-mediated VDR activation led to varied responses in different endothelial cell populations. Calcitriol at nanomolar concentrations inhibited cell growth of isolated tumor endothelium (5, 14, 22); however, the growth of microvascular endothelial cells isolated from Matrigel plugs was only minimally affected by similar treatment. Resistance to calcitriol’s effects was also observed in endothelial cells of other normal tissues, including those isolated from mouse brain, lung, and yolk sac (5, 14). Calcitriol elicited cell cycle arrest in tumor endothelial cells by inducing expression of p21 and p27, which was not observed in calcitriol-treated normal endothelial cells (14). The induction of p21 and p27 was accompanied by a reduction in DNA synthesis and a significant increase in apoptosis in tumor endothelial cells but not endothelial cells from benign tissue. Furthermore, there was a distinct difference in modulation of key survival and apoptotic signaling molecules by calcitriol treatment; there was a significant reduction in phospho-Erk, phospho-Akt, and the anti-apoptotic protein Bcl-2 in tumor endothelial cells (Fig. 2). Also, an increase in caspase-3 expression and poly(ADP)-ribose polymerase cleavage was observed in tumor endothelial cells but not in normal endothelial cells (14).

There would be significant clinical implications if potent antiangiogenic agents that are candidates for cancer therapy are found to exert comparable effects on normal vasculature, such as impeding physiologically important normal angiogenic processes, wound healing, or menstruation. However, the selective growth inhibitory effects of calcitriol observed only in tumor endothelium could translate into a clinically significant difference in therapeutic efficacy. Treatment of tumor-bearing mice with calcitriol significantly reduced the mean tumor microvessel density marked by CD31 staining of endothelial cells, with little effect observed in the vasculature at nontumor sites such as Matrigel plugs (48). The reduction in mean vessel density in tumors correlated with an increased number of apoptotic endothelial cells and caspase-3 activation in double-staining experiments. It is important to note that the tumor and Matrigel plugs were generated on opposing flanks of the same mouse; therefore, the microvasculatures established at the two sites were comparable, albeit induced by different microenvironments.

The role of VDR in calcitriol-mediated growth inhibitory effects in tumor endothelium was evident when tumor endothelial cells isolated from a prostate tumor xenograft implanted in VDR-knockout (VDR-KO) mice failed to respond to calcitriol in vitro (12). In this model, murine prostate adenocarcinoma (TRAMP)-C2 prostate adenocarcinoma tumors were generated in VDR wild-type hosts and VDR knockout mouse hosts, and tumor endothelial cells were isolated from tumors in both hosts for analysis. Since formation of blood vessels within the tumor requires participation from host cells (24), the isolated endothelial cells portray the genetic makeup of the host. Tumor endothelial cells isolated from VDR wild-type mice showed an increase in VDR protein upon treatment with calcitriol and trans-activation of the CYP24 promoter (12). This led to an induction of G0/G1 cell cycle arrest and a decrease in S phase cells. In contrast, upregulation of VDR and induction of CYP24 were not observed in endothelial cells derived from tumors growing in VDR-KO mice.

The absence of VDR in endothelial cells of KO animals resulted in aberrant tumor vasculature; the tumor microvasculature was enlarged and was associated with fewer pericytes compared with the tumor vasculature in wild-type animals (12). Structural and functional deficiencies in tumor vasculature could result in limited delivery of chemotherapeutic agents, which would enhance resistance to chemotherapy (64). The increased abnormalities found in the tumor vasculature of VDR-KO mice implied that VDR could modulate differentiation and functionality of the vasculature in addition to mediating calcitriol’s antiproliferative effects. In the tumors grown in VDR-KO background, upregulation of angiogenic factors such as VEGF, angiopoietin-1, HIF-1α, and PDGF was observed. The correlation of VDR loss with increased levels of proangiogenic factors suggested that VDR had direct and/or indirect suppressive effects on the transcription of these factors. Such inhibitory effects were also observed in other cell models, including human anulus and neutrophil cells and Kaposi sarcoma cells (33, 42, 62). Interestingly, VDR was also shown to improve the angiogenic properties of endothelial progenitor cells by inducing various factors, including VEGF (34).

Therefore, in consideration of targeting VDR in cancer therapy, it would be important to investigate whether VDR...
inhibitory effects on the activity of angiogenic factors are applicable to the tumor vasculature across different tumor types, including CaP. Studies such as those that use cross-breeding of VDR-KO mice (56) or mice expressing VDR-KO under the influence of the endothelial-specific promoter Tie-1 (46), with TRAMP (28) or LPB-Tag (50) transgenic mouse prostate cancer models, will allow mechanistic studies of the role of VDR in tumor endothelium in spontaneously arising prostate adenocarcinomas. In fact, LPB-Tag tumors progressed more rapidly in VDR-KO mice compared with wild-type animals (67); however, the role of VDR in the tumor vasculature was not examined. Molecular evidence obtained from such studies will provide invaluable insight into the role of VDR activity in regulation of the neovasculature during tumor angiogenesis.

**AR and VDR Cross-Talk**

In prostate cancer cells, activation of AR signaling led to suppression of VDR trans-activation (96), which was probably due to competition for the same pool of coregulators required for receptor-mediated trans-activation. Interestingly, calcitriol demonstrated limited growth inhibitory effects on castration-sensitive lymph node carcinoma of the prostate (LNCaP) cells grown in medium lacking androgens and no effect on castration-resistant derivatives of LNCaP cells (69). Furthermore, the use of antiandrogens such as bicalutamide repressed calcitriol’s anti-tumor effect by downregulating VDR-induced expression of AS3 (APRIN) (69). However, it was noted that such negative regulation of VDR by Casodex was limited to LNCaP-derived prostate cancer cell lines and that androgen deprivation therapy should not obviate the concurrent use of VDR agonists (69). The interdependence of AR and VDR may vary between different prostate cancer cell lines, and the cross-talk between AR and VDR has not been investigated thoroughly in prostate tumor endothelial cells, especially those from castration-resistant prostate tumors. Therefore, the effects of varying AR and VDR agonists or analogs that activate these receptors may result in differential modulation of nuclear receptor cross-talk and provide new approaches for selective inhibition of growth of prostate cancers (66).

**Clinical Effects of Modulating AR and VDR Signaling on Prostate Vasculature**

The historic paradigm of ADT as a monofunctional treatment of CaP and BPH is founded on the hypothesis that the prostate secretory epithelial cell/cancer epithelial cell is the

---

**Fig. 2. Effects of androgen receptor (AR) and vitamin D receptor (VDR) signaling activation in prostatic tumor endothelium.** When T enters the cell, it is converted to DHT before binding to the AR. Homodimers of ligand-bound AR translocate into the nucleus and bind to androgen-responsive elements (AREs), inducing transcription of AR target genes that modulate endothelial cell proliferation and survival. Similarly, when 1,25-dihydroxycholecalciferol (1,25-D3) enters a cell, it binds to the VDR in the cytoplasm. Activated VDR heterodimerizes with retinoid X receptor (RXR) before the complex translocates into the nucleus. In tumor endothelium, the ligand-bound VDR-RXR-heterodimer binds to DNA harboring vitamin D response elements (VDREs) and induces expression of genes that inhibit cell proliferation. Due to DNA methylation, this heterodimer cannot bind to the promoter of CYP24, leading to reduced CYP24 expression and reduced calcitriol metabolism in the cells.
only androgen-sensitive cell type within in the complex and highly interactive prostate tissue microenvironment and that AR functions independent of other nuclear receptors. However, several pieces of evidence suggest strongly that human prostate endothelial cells demonstrate cell-type-specific responses to ADT, including 1) the empirical observation that ADT induced a reduction of hematuria due to BPH, 2) treatment with AR antagonists (e.g., flutamide or bicalutamide) and steroid metabolism inhibitors (e.g., finasteride or dutasteride) reducing bleeding during radical prostatectomy surgery, and 3) treatment of patients with gonadotrophin-releasing hormone agonist (bicalutamide/goserelin), or dutasteride, producing a profound vascular collapse in the prostate without collateral systemic vascular perturbation. Consequently, human prostate endothelial cells represent an unexplored target for androgens and ADT. In accord with these observations, our group demonstrated for endothelial cells from both human CaP tissue and human benign prostate tissue that 1) prostate endothelial cells express AR (30), 2) ADT induces apoptosis in a prostate endothelial cell that preceded the peak of apoptosis in the cancer epithelial cell compartment by several days (29), and 3) ADT-induced cell death results in acute loss of prostate vascular integrity that allows leakage of serum components (including androgens/steroids) into the interstitial tissue space (29).

ADT-induced transient destabilization of the human prostate endothelial cell compartment may present a “therapeutic window” for delivery of chemotherapeutic agents. Therefore, the study of the regulatory role of androgens in the prostate microvasculature may provide the molecular basis for development of new therapeutic modalities. This paradigm-shifting approach would change the monolithic paradigm of ADT as a first-line therapy that is focused on induction of apoptotic death in CaP cells to a dynamic paradigm where ADT is employed in a neoadjuvant setting to improve therapeutic efficacy of conventional and new treatment modalities. This new approach would capitalize on the “therapeutic window” opened by the acute apoptotic death of prostate endothelial cells to allow access to the interstitial tissue space for chemotherapeutic agents that are usually blocked by the intact endothelial barrier. Moreover, these studies could provide new biomarkers and potential therapeutic targets for agents to inhibit neoangiogenesis more effectively after ADT, blocking and/or delaying recurrence and making ADT curative instead of palliative.

VDR, on the other hand, can be activated by calcitriol in both normal and tumor vasculature of the prostate. However, as described above, VDR activation results in an antiproliferative effect only on tumor endothelium, without the normal vasculature being affected. Hence, calcitriol may potentially affect prostate tumor angiogenesis without toxicity to the normal vasculature. Clinically, the maximum tolerated dose (MTD) of calcitriol alone and in combination with a number of cytotoxic agents and/or glucocorticoids was determined in phase I studies (68, 97, 103). Furthermore, in a phase II trial in patients with androgen-independent prostate cancer, the combination of dexamethasone and calcitriol resulted in an enhanced but still limited anti-tumor effect (98). However, these studies were hampered by limited drug bioavailability to the tumor because drug dosage was constrained by hypercalcemia, a confounding adverse effect associated with calcitriol treatment (102).

Bioavailability of calcitriol is also limited by endogenous 25-hydroxylase (CYP24) activity. CYP24 is the key enzyme responsible for initiation of the vitamin D degradation pathway by directing the side chain metabolism of vitamin D metabolites, including calcitriol (75). CYP24 is expressed in most vitamin D target tissues and can be induced by calcitriol (78), providing a negative feedback regulation for attenuation of the effects of excessive calcitriol levels. Interestingly, CYP24 was found to be epigenetically silenced in endothelium of multiple preclinical tumor models, including TRAMP, murine radiation-induced fibrosarcoma, and murine squamous cell carcinoma, and the loss of CYP24 activity may explain the enhanced cytotoxic effects of calcitriol in these cells (13). A different study observed that CYP24 was hypermethylated in the endothelium of human prostate cancer tissues (17), further supporting the clinical use of vitamin D against tumor vasculature. Hence, CYP24 expression may provide the basis for the selective VDR-mediated growth inhibitory effects in tumor endothelium without affecting normal vasculature.

Since most clinical studies with calcitriol were designed primarily to determine the anti-tumor effects of calcitriol on tumor cells, it is unclear whether the anti-tumor effects observed were also attributable to effects of calcitriol on tumor endothelium or whether calcitriol at the MTD demonstrated a selective growth inhibition to tumor endothelium without affecting normal vasculature. More clinical studies are necessary to validate the use of calcitriol in targeting tumor endothelium.

Conclusion

Recent evidence demonstrated that AR and VDR have major roles in maintenance of homeostasis of human prostate endothelial cells, and both receptors are druggable targets that allow comparison of independent and concurrent therapies. However, there are several important questions related to the specific roles of AR and VDR in endothelial cells that remain unanswered. 1) Can AR and VDR expression levels in tumor-associated prostate endothelial cells predict the angiogenic capacity of prostate cancer and thus serve as a prognostic marker for CaP? 2) Do AR and VDR function similarly in benign prostate-associated endothelial cells as they do in tumor-associated prostate endothelial cells? And 3) What is the role of these receptors in the maintenance of homeostasis of prostate endothelial cells in benign tissue and/or in prostate cancer tissue? Considering that both AR and VDR modulate endothelial cell proliferation, can these two receptors differentially affect other endothelial cell processes, such as differentiation, migration, branching, and maturation into functional vasculature in normal and diseased prostate, and if so, do they have similar or opposite effects?

Evidence of expression of functional AR in human prostate endothelial cells in CaP tissue and of the acute effect of ADT on human prostate vascular integrity indicate that human prostate vasculature has a unique potential as a first-line target for ADT. Similarly, modulation of VDR-activated signaling with calcitriol or vitamin D analogs may be effective in selective targeting of tumor endothelium in the prostate without affecting the normal endothelium. Such selectivity is particularly important to avoid adverse effects commonly observed with current antiangiogenic agents. Understanding the molecular mechanisms involved in each signaling pathway could be beneficial for identification of common targets for prostate endothelial cells.
REFERENCES


ROLE OF AR AND VDR IN PROSTATE VASCULARITY

ROLE OF AR AND VDR IN PROSTATE VASCULATURE


96. Tissot JP. Androgen-receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity. *Endocrine* 26: 1–9, 2005.


AJP-Endocrinol Metab • doi:10.1152/ajpendo.00602.2012 • www.ajpendo.org